Diadema Partners »

Travere Therapeutics shares owned by Diadema Partners

Quarter-by-quarter ownership of Travere Therapeutics (TVTX) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Travere Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Travere Therapeutics held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Travere Therapeutics by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-09-30 $7.2k 300 23.90

More positions owned by Diadema Partners

Jazz Pharmaceuticals Shs Usd (JAZZ)
Soleno Therapeutics (SLNO)
Uniqure Nv SHS Put Option (QURE)
Regeneron Pharmaceuticals (REGN)
Viking Therapeutics (VKTX)
Bristol Myers Squibb (BMY)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
BioMarin Pharmaceutical (BMRN)
Avidity Biosciences Ord (RNA)
Agios Pharmaceuticals Call Option (AGIO)
Ultragenyx Pharmaceutical (RARE)
Incyte Corporation Call Option (INCY)
Intellia Therapeutics Call Option (NTLA)
Vaxcyte (PCVX)
Eli Lilly & Co. Put Option (LLY)

View all positions for Diadema Partners

Top funds holding Travere Therapeutics

Henderson Group
BlackRock
Armistice Capital
Vanguard Group
Macquarie Group
Perceptive Advisors
Adage Capital Partners GP
State Street Corporation
FMR
Rock Springs Capital Management
Emerald Advisers
Geode Capital Management
Renaissance Technologies
Stephens Investment Management Group
Deutsche Bank Aktiengesellschaft

View all funds holding Travere Therapeutics